The company anticipates gross proceeds of approximately USD4.9 m.
RXi has also agreed to issue to the investors unregistered warrants to purchase up to 1,132,953 shares of common stock.
The company intends to use the net proceeds from this offering for general corporate purposes, including but, not limited to, funding its preclinical and clinical development, other research and development activities and for general and administrative expenses.
RXi Pharmaceuticals develops innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval